Loading...
Prime Medicine, Inc.
PRME•NASDAQ
HealthcareBiotechnology
$1.69
$0.33(24.26%)
Prime Medicine, Inc. (PRME) Stock Overview
Explore Prime Medicine, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-1.54
↑ 1.14%
EPS Growth
$-1.54
↑ 24.31%
Operating Margin
-496.20%
↓ 5.84%
ROE
-125.05%
↑ 1.14%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
0
Buy
1
Hold
2
Sell
0
Strong Sell
0
Price Targets
Low$15.00
Average$15.00
High$15.00
Company Profile
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
CEO
Dr. Jeremy S. Duffield M.D., Ph.D.
Employees
214
Headquarters
21 Erie Street, Cambridge, MA
Founded
2022